Wong Kin Sang – Country Manager, Lundbeck Malaysia
Wong Kin Sang, country manager of Lundbeck Malaysia, walks us through the mental health issues’ perception in Malaysia and the important work Lundbeck has done to bring more awareness to…
Address: Menara Hap Seng, No. 1 & 3,10th Floor, Jalan P Ramlee, 50250 Kuala Lumpur ,Malaysia
Tel: 603-5121 5819
Web: http://www.lundbeck.com/global
We are a research-based company. We engage in research to find new drugs for treatment of CNS disorders, includ ing depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, epilepsy and insomnia.
These are serious disorders. They affect not only patients, but also their families and friends. Besides the stress of having a CNS disorder, patients are often exposed to prejudice because, in many sections of society, there is still far too little understanding of how adversely a CNS disorder affects an individual’s life.
We have taken upon ourselves the task of improving quality of life for persons with a psychiatric or neurological disorder, and we are working intensely to find and develop new and improved drugs. We believe that we can make a significant difference, and we are happy to do so in cooperation with others.
Depression, schizophrenia, Alzheimer’s, Parkinson’s and sleep disorders have their foundation in the central nervous system – our key focus areas. Here are some in depth information to help you better understand these diseases.
Our products
Cipralex® Antidepressant Ebixa® Anti-Alzheimer’s Azilect® Anti-Parkinson’s Serdolect® Schizophrenia Circadin® Insomnia Sabril® Epilepsy Xenazine® Huntington’s disease
Wong Kin Sang, country manager of Lundbeck Malaysia, walks us through the mental health issues’ perception in Malaysia and the important work Lundbeck has done to bring more awareness to…
Lundbeck’s country manager gives a thorough overview of CNS disorders in Malaysia and states: “It is important to remind everyone that mental health conditions or brain diseases are not to…
You have worked in the pharmaceutical industry for many years starting with Novartis and you have spent the last eight years working for Lundbeck. What are the major changes that…
“Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of…
“Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of…
“Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of…
Klinsel’s CEO discusses the company’s ambitions of growth in a very competitive CRO market and stresses that local experience is truly a distinguishing factor and this is why they are…
Novo Nordisk Malaysia’s general manager shares the ongoing fight to cure diabetes and talks about the necessity to raise awareness, with for instance their current MoU with the ministry of…
Malaysia Healthcare Travel Council’s CEO is proud of her country’s healthcare system and their efforts at attracting medical tourists from all over the world, with the support of the healthcare…
Mundipharma Malaysia’s country manager discusses his company’s aim to become a reference in Malaysia for pain management, on the back of the tremendous 48 percent growth of the business last year. …
Lundbeck’s country manager gives a thorough overview of CNS disorders in Malaysia and states: “It is important to remind everyone that mental health conditions or brain diseases are not to…
MMA’s president shares the reasons why Malaysia is ranked today third in terms of healthcare quality, with a very efficient public system, high quality doctors and strong government support. However,…
IMS in Malaysia is possibly the first company to have signed a Memorandum of Understanding with the government for data provision. IMS Health’s general manager introduces this landmark and also…
Aspen Malaysia’s country manager details the company’s success in the country with a specific business model based on acquiring and remarketing originators. Although Aspen is a renowned generic player, market dynamics…
MGCC’s Executive Director discusses the opportunities and challenges for German pharma and healthcare companies to invest in Malaysia, at a time where most have decided to invest and base their…
See our Cookie Privacy Policy Here
